Advertisement
Swiss medical technology company Ypsomed plans to build its first U.S. manufacturing facility in Holly Springs, North Carolina, with an initial investment of USD 200 million. The plant will create around 100 jobs, potentially doubling in the coming years, and is expected to start supplying the U.S. market by late 2027. Amid 39% U.S. tariffs on Swiss goods, the expansion complements Ypsomed's recent plant in China, investment in Germany, and domestic production growth in Switzerland. The move aims to meet increasing global demand and strengthen supply reliability in the U.S.
Swiss medical technology company Ypsomed has revealed plans to set up its first manufacturing facility in the United States, investing an initial USD 200 million in Holly Springs, North Carolina. The facility, focused on producing self-injection systems, is expected to create around 100 jobs, with the company aiming to nearly double the workforce in the coming years to meet rising demand. The plant is scheduled to start supplying the U.S. market by the end of 2027. Advertisement
The investment comes as Swiss companies navigate U.S. trade policies, which currently impose 39% tariffs on goods imported from Switzerland. Ypsomed has been steadily expanding its international presence: earlier this year, it opened its first manufacturing plant in China, and it is investing several hundred million CHF to grow operations in Schwerin, Germany. In Switzerland, the company is increasing domestic production at its Solothurn facility, committing 200 million CHF (around USD 248 million) to boost capacity.
The U.S. facility is part of Ypsomed's strategy to diversify production and ensure reliable supply for a key market. By establishing a local base, the company aims to shorten delivery times, improve service for U.S. customers, and reduce risks linked to trade tariffs. The expansion also aligns with Ypsomed's global growth plan, complementing its operations in Europe and Asia while addressing rising demand for self-injection solutions worldwide.
Source Reuters
5th Jun, 2025
25th May, 2023
11th May, 2023
27th Apr, 2023
Advertisement
Facebook
Whatsapp
